Targeting cortisol to treat Alzheimer’s disease and cognitive impairment

Biotech company Actinogen Medical is developing Xanamem, a drug designed to inhibit the increased production of cortisol in the brain, which has been linked to cognitive decline and Alzheimer’s disease.

Go to the profile of Actinogen
Nov 06, 2018
0
0
Page of
Go to the profile of Actinogen

Actinogen

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases. The Actinogen Medical management team and clinical and scientific advisory boards include world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug development and clinical trial management. Actinogen Medical’s lead drug candidate XanamemTM has been specifically designed to reduce production of excess cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical is currently conducting a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of 10mg once daily of XanamemTM in subjects with mild dementia due to Alzheimer’s disease. The trial, named XanADu, will enrol 174 patients at 25 research sites across Australia, the UK and the USA. Recruitment and treatment of patients began in 2017 and is expected to complete in Q4 CY18, with results expected in early 2019. For more information visit www.actinogen.com.au For more information on the XanADu trial visit www.clinicaltrials.gov with identifier: NCT02727699

No comments yet.